NARCOMS says registry survey data show semaglutide or tirzepatide use among people with MS, with 5.5% currently taking one.
Recap by typeshit. Post by @narcoms_now on Instagram.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Dr Alo argues semaglutide's bigger story is heart protection, citing SELECT trial results showing fewer cardiovascular events in people without diabetes.
Her point: food industry habits and sedentary lifestyles that drove weight gain are still there, even as millions start these medications.
Loading…